Esperion Therapeutics Inc Asset Resilience Ratio
Esperion Therapeutics Inc asset resilience ratio. Esperion Therapeutics Inc (ESPR) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ESPR days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Esperion Therapeutics Inc (2002–2023)
Asset resilience ratio of Esperion Therapeutics Inc from 2002 to 2023. This chart shows how Esperion Therapeutics Inc's Asset Resilience Ratio has changed over time. Read Esperion Therapeutics Inc (ESPR) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Esperion Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Esperion Therapeutics Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Esperion Therapeutics Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Esperion Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Esperion Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Esperion Therapeutics Inc Asset Resilience Ratio by Year (2002–2023)
Esperion Therapeutics Inc asset resilience ratio by year from 2002 to 2023. The table below shows the annual Asset Resilience Ratio data for Esperion Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $205.80 Million | -- |
| 2022-12-31 | 16.97% | $42.09 Million | $247.94 Million | +3.76pp |
| 2021-12-31 | 13.22% | $50.44 Million | $381.59 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $353.26 Million | -- |
| 2019-12-31 | 16.16% | $34.65 Million | $214.45 Million | -52.89pp |
| 2018-12-31 | 69.05% | $99.05 Million | $143.45 Million | +9.40pp |
| 2017-12-31 | 59.65% | $165.73 Million | $277.83 Million | -11.07pp |
| 2016-12-31 | 70.72% | $173.42 Million | $245.21 Million | +25.07pp |
| 2015-12-31 | 45.65% | $134.93 Million | $295.57 Million | +31.14pp |
| 2014-12-31 | 14.51% | $20.80 Million | $143.34 Million | +10.01pp |
| 2013-12-31 | 4.50% | $3.53 Million | $78.29 Million | -3.97pp |
| 2002-12-31 | 8.47% | $4.35 Million | $51.41 Million | -- |
About Esperion Therapeutics Inc
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary h… Read more